Sam Brusco, Associate Editor06.13.22
Orthobiologics company Ortho Regenerative Technologies (Ortho RTI) has initiated patient recruitment for its U.S. Phase I/II rotator cuff tear repair clinical trial.
These clinical sites are currently recruiting and screening patients for randomization in the Phase I/II study:
"I am pleased with the recent progress in accelerating our U.S. Phase I/II clinical trial related activities," Ortho RTI CEO Philippe Deschamps told the press. "The budget negotiations have been completed for all centers but one, the majority of clinical trial agreements have been executed with site initiation visits either completed or soon to be completed. We are also very pleased with our choice of clinical trial sites. They were specifically chosen for the volume of patients they treat, the outstanding qualifications of their clinical investigators and their reputation for research excellence. We look forward to start reporting soon on patient enrolment status.”
Ortho RTI will report regularly on clinical milestones. The company is also exploring further applications for its Drug/Biologic PRP combination product.
These clinical sites are currently recruiting and screening patients for randomization in the Phase I/II study:
- Rothman Institute, Pa.
- OrthoIndy Research Foundation, Ind.
- University Orthopedics, Pa.
- Tucson Orthopedics, Ariz.
- Holy Cross Orthopedic Institute, Fla.
- OrthoVirginia Institute, Va.
- Remaining four sites to be activated over the coming months.
"I am pleased with the recent progress in accelerating our U.S. Phase I/II clinical trial related activities," Ortho RTI CEO Philippe Deschamps told the press. "The budget negotiations have been completed for all centers but one, the majority of clinical trial agreements have been executed with site initiation visits either completed or soon to be completed. We are also very pleased with our choice of clinical trial sites. They were specifically chosen for the volume of patients they treat, the outstanding qualifications of their clinical investigators and their reputation for research excellence. We look forward to start reporting soon on patient enrolment status.”
Ortho RTI will report regularly on clinical milestones. The company is also exploring further applications for its Drug/Biologic PRP combination product.